Pentixapharm Acquires Target Discovery Business of Glycotope


WĂśRZBURG, Germany and BERLIN, July 03, 2024 (GLOBE NEWSWIRE) -- Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a range of malignancies, has announced the execution of an agreement, effective July 1st, to acquire the target discovery business of Berlin-based Glycotope GmbH.

Read the original here:
Pentixapharm Acquires Target Discovery Business of Glycotope

Related Posts